Fosamax and Boniva Drug Lawsuit Charges Permanent and Severe Injuries from Long-Term Bisphosphonate Use

NEW YORK--(BUSINESS WIRE)-- Kent Klaudt of the national plaintiffs’ law firm Lieff Cabraser Heimann & Bernstein, LLP announced that Reba Inez Patton and her husband Patrick Patton of Tennessee have filed a lawsuit in the Superior Court of New Jersey against Merck & Co., the manufacturer of Fosamax, and GlaxoSmithKline, LLC, the manufacturer of Boniva, alleging these prescription drugs, which fall within the category of drugs known as bisphosphonates, increase the risk of atypical bone fractures and caused Mrs. Patton severe and permanent injuries.

Mrs. Patton was prescribed both Fosamax and Boniva. Mrs. Patton used Fosamax from approximately 2001 to 2006, and Boniva from approximately 2006 to 2010. On December 10, 2010, Mrs. Patton suffered a low energy, atypical femoral fracture when she took a step to walk up a flight of stairs.

"I wish this never happened to me. When I walk, it is scary because I do not want to fall again,” stated Mrs. Patton.

Bisphosphonates such as Fosamax and Boniva are intended to slow bone loss associated with osteoporosis. However, as the lawsuit charges, long-term use of Fosamax and Boniva causes weak or brittle bones, resulting in a rare type of low energy or low trauma femur fracture.

“Merck and GlaxoSmithKline negligently marketed these bisphosphonate products, which lack long-term benefits and also pose significant dangers to patients, especially those who have been on the drugs for many years,” commented attorney Klaudt.

The complaint also charges that Merck and GlaxoSmithKline failed to provide physicians and patients with sufficient instructions and warnings regarding the risk of severely suppressed bone turnover, resulting in stress fractures. Klaudt stated, “Neither doctors nor patients were warned by the manufacturers of these horrible atypical femur fractures caused by long-term use of bisphosphonates.”

Mrs. Patton charges in the complaint that she will require ongoing medical care and treatment due to her severe and permanent injuries, including severely suppressed bone turnover and a severe fracture in her left femur, fear of developing other harmful conditions, additional fractures, and pain and mental anguish.

“The accident changed a good part of my life; it put a lot of extra burden on my family. I just do not want this to happen to anyone else,” Mrs. Patton added.

Legal Resources for Injured Fosamax, Boniva, and Osteoporosis Drug Patients

If you or a family member have suffered femur fractures after being prescribed Fosamax, Boniva, or osteoporosis drugs you may be eligible to file a claim. You can learn more about your legal rights and osteoporosis drug lawsuits on our website.

About Lieff Cabraser

Lieff Cabraser Heimann & Bernstein, LLP, with offices in San Francisco, New York, and Nashville, is a nationally recognized law firm committed to advancing the rights of investors and promoting corporate responsibility.

Since 2003, the National Law Journal has selected Lieff Cabraser as one of the top plaintiffs' law firms in the nation. In compiling the list, the National Law Journal examined recent verdicts and settlements in addition to overall track records. Lieff Cabraser is one of only two plaintiffs' law firms in the United States to receive this honor for the last eight consecutive years.

For more information about Lieff Cabraser and the firm's representation of injured consumers, please visit http://www.lieffcabraser.com.



CONTACT:

Lieff Cabraser Heimann & Bernstein, LLP
Kent L. Klaudt, Esq., 800-541-7358

KEYWORDS:   United Kingdom  United States  Europe  North America  California  New Jersey  New York

INDUSTRY KEYWORDS:   Seniors  Health  Pharmaceutical  Professional Services  Legal  Consumer

MEDIA:

Logo
 Logo

Suggested Articles

AbbVie and Allergan were already jumping through hoops for their merger before a new tax added hundreds of millions to the cost.

Avastin and Herceptin saw U.S. slowdown that's “not very pronounced” after bioisim launched, but Roche execs still warn of "a significant impact.…

Novo Nordisk, which recently completed a wastewater treatment plant for its massive U.S. API site, has made a gift of the $40 million facility.